Neuroblastoma screening: The Canadian experience
✍ Scribed by Lemieux, Bernard ;Auray-Blais, Christiane ;Giguére, Robert ;Scriver, Charles R.
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 284 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
If neuroblastoma is a homogeneous disease, a screening program may be appropriate to detect the condition during the preclinical phase, before symptomatic disease, and it may decrease the overall mortality rate. Six pilot European screening studies were performed in infants to study the feasibility
Texas were screened for neuroblastoma. An enzyme-linked immunoadsorbent assay (ELISA) for homovanillic acid (HVA) and vanillylmandelic acid (VMA) used
## BACKGROUND. The Quebec Neuroblastoma Screening (QNS) Project completed a 5-year program for measuring urinary vanillylmandelic acid (VMA)/homovanillic acid (HVA) levels at age 3 weeks and/or 6 months in 89% of 476,603 Quebec-born infants from 1989 -1994; 45 screening positive preclinical cases